Editor/NN
’/CD
s/NNS
Introduction/NN
to/TO
This/DT
Issue/NN
(/(
G/NN
&/CC
I/NN
16:3/CD
,/,
2018/CD
)/)
./.
====================
The/DT
identification/NN
of/IN
prognostic/JJ
indicators/NNS
is/VBZ
one/CD
of/IN
the/DT
fundamentally/RB
important/JJ
issues/NNS
in/IN
the/DT
management/NN
of/IN
cancer/NN
./.
====================
In/IN
terms/NNS
of/IN
mutational/JJ
burden/NN
,/,
prostate/NN
cancer/NN
is/VBZ
relatively/RB
silent/JJ
,/,
and/CC
the/DT
therapeutic/JJ
options/NNS
for/IN
it/PRP
,/,
including/VBG
targeted/VBN
therapy/NN
,/,
are/VBP
relatively/RB
limited/JJ
./.
====================
Androgen/NN
deprivation/NN
therapy/NN
is/VBZ
an/DT
important/JJ
therapeutic/JJ
option/NN
for/IN
prostate/NN
cancer/NN
;/:
however/RB
,/,
a/DT
substantial/JJ
proportion/NN
of/IN
prostate/NN
cancers/NNS
progress/VBP
into/IN
castration-resistant/JJ
prostate/NN
cancer/NN
,/,
which/WDT
does/VBZ
not/RB
respond/VB
to/TO
androgen/NN
deprivation/NN
therapy/NN
./.
====================
In/IN
this/DT
issue/NN
,/,
Dr./NNP
Seon-Young/JJ
Kim/NN
’/CD
s/NNS
group/NN
reports/NNS
whole-genome/WP$
sequence/NN
data/NNS
from/IN
four/CD
pairs/NNS
of/IN
primary/JJ
prostate/NN
cancer/NN
and/CC
castration-resistant/JJ
prostate/NN
cancer/NN
samples/NNS
./.
====================
In/IN
addition/NN
to/TO
their/PRP$
scientific/JJ
exploration/NN
,/,
they/PRP
have/VBP
released/VBN
this/DT
dataset/NN
for/IN
the/DT
research/NN
community/NN
as/IN
a/DT
resource/NN
for/IN
further/JJ
understanding/NN
the/DT
progression/NN
of/IN
castration-resistant/JJ
prostate/NN
cancer/NN
./.
====================
Dr./NNP
In-Jin/NN
Jang/NN
’/CD
s/NNS
group/NN
has/VBZ
reported/VBN
a/DT
case/NN
study/NN
of/IN
how/WRB
pharmacogenomics/NNS
and/CC
pharmacometabolomics/NNS
can/MD
be/VB
used/VBN
to/TO
characterize/VB
safety/NN
and/CC
pharmacokinetic/JJ
profiles/NNS
in/IN
early-phase/JJ
new/JJ
drug/NN
development/NN
clinical/JJ
trials/NNS
./.
====================
Their/PRP$
data/NNS
support/VBP
that/DT
integrated/VBN
multi-omics/NNS
analysis/NN
can/MD
be/VB
useful/JJ
for/IN
elucidating/VBG
the/DT
various/JJ
characteristics/NNS
of/IN
new/JJ
drug/NN
candidates/NNS
in/IN
early-phase/JJ
clinical/JJ
trials/NNS
./.
====================
The/DT
other/JJ
papers/NNS
regard/RB
a/DT
chemoinformatics/NNS
approach/NN
for/IN
the/DT
antibacterial/JJ
evaluation/NN
of/IN
fluoroquinolones/NNS
,/,
a/DT
genome-wide/JJ
association/NN
study/NN
analysis/NN
of/IN
pork/NN
quality/NN
,/,
and/CC
a/DT
text/JJ
corpus/FW
system/NN
for/IN
G/NN
&/CC
I/NN
,/,
termed/VBN
GNI/NN
Corpus/NN
version/NN
1.0/CD
,/,
all/DT
of/IN
which/WDT
are/VBP
interesting/JJ
and/CC
useful/JJ
for/IN
genomic/JJ
research/NN
./.
====================
For/IN
further/RBR
details/VBZ
,/,
please/NN
visit/FW
the/DT
G/NN
&/CC
I/NN
homepage/NN
(/(
https/NNS
:/:
//genominfo.org/JJ
)/)
./.
====================
